Dr. Rodger Novak is the co-founder, president and chairman of CRISPR Therapeutics, a Switzerland-based biotechnology company he helped found in 2013.
Since its inception in 2013, Dr. Novak has been at the helm of CRISPR and its emerging technologies. From 2013 to 2017 Dr. Novak served as the company’s CEO, helping turn CRISPR into a clinical stage company by building up its U.S.-based operations to more than 150 employees and taking the company public in 2016.
During his tenure as CEO, Dr. Novak helped raise more than $400 million in capital, established a joint venture with Bayer and closed a multi-billion dollar deal with Vertex Pharmaceuticals.
He left his position as CEO in December 2017 to serve as the company’s president and chairman of the board. He also serves as the director of Casebia Therapeutics, CRISPR’s joint venture with Bayer AG.
Dr. Novak was a serial entrepreneur and experienced pharmaceutical and biotechnology executive long before CRISPR’s founding. He previously served as the global head of infectious disease and research and development with Sanofi, based in Paris. While there, he was tasked with discovery and R&D around antibiotics, antivirals and drugs for the diseases present in the developing world.
In 2006, he co-founded Nabriva Therapeutics, an antibacterial development company operating out of Vienna, Austria. He served as chief operating officer at Nabriva for almost six years. Dr. Novak’s career began at Sandoz, where he worked as the deputy head of the antibiotic research institute. Nabriva is largely a spin-off of Dr. Novak’s work at Sandoz.
He is also a former professor of microbiology at the Vienna Biocenter in Austria. He earned his M.D. from Philipps University in Marburg, Germany and his U.S. medical license the following year. Dr. Novak continued his post-doctoral work in New York City, serving at The Rockefeller University, St. Jude’s Children’s Research Hospital and the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center.
He is listed as co-inventor for five patents, and he has authored articles for Nature, Molecular Cell, and Nature Medicine.
What is Rodger Novak's net worth?
The estimated net worth of Rodger Novak is at least $27.08 million as of June 30th, 2021. Dr. Novak owns 573,007 shares of CRISPR Therapeutics stock worth more than $27,080,311 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Novak may own. Learn More about Rodger Novak's net worth.
How old is Rodger Novak?
Dr. Novak is currently 55 years old. There are 4 older executives and no younger executives at CRISPR Therapeutics. The oldest executive at CRISPR Therapeutics is Dr. Matthew Porteus M.D., Ph.D., Scientific Founder & Advisory Board Member, who is 56 years old. Learn More on Rodger Novak's age.
How do I contact Rodger Novak?
Has Rodger Novak been buying or selling shares of CRISPR Therapeutics?
Rodger Novak has not been actively trading shares of CRISPR Therapeutics during the past quarter. Most recently, Rodger Novak sold 25,000 shares of the business's stock in a transaction on Wednesday, June 30th. The shares were sold at an average price of $165.00, for a transaction totalling $4,125,000.00. Following the completion of the sale, the president now directly owns 573,007 shares of the company's stock, valued at $94,546,155. Learn More on Rodger Novak's trading history.
Who are CRISPR Therapeutics' active insiders?
Are insiders buying or selling shares of CRISPR Therapeutics?
In the last year, insiders at the sold shares 14 times. They sold a total of 192,740 shares worth more than $12,514,312.47. The most recent insider tranaction occured on November, 11th when CEO Samarth Kulkarni sold 30,000 shares worth more than $1,668,600.00. Insiders at CRISPR Therapeutics own 4.1% of the company.
Learn More about insider trades at CRISPR Therapeutics. Information on this page was last updated on 11/11/2024.
